Obicetrapib effects on antioxidant levels in blood, HDL, and eye tissue
A Randomized, Double-Blind, Placebo-Controlled Parallel Trial to Assess the Effects of Obicetrapib on Levels of Antioxidants in Plasma and HDL Particles in Healthy Volunteers: The VERMEER Study
PHASE2 · NewAmsterdam Pharma · NCT06982508
This trial will test whether taking obicetrapib daily for four months helps healthy adults absorb more antioxidants into their blood, HDL particles, and retinal tissue compared with a placebo.
Quick facts
| Phase | PHASE2 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | NewAmsterdam Pharma (industry) |
| Locations | 1 site (Miami Gardens, Florida) |
| Trial ID | NCT06982508 on ClinicalTrials.gov |
What this trial studies
Healthy adult volunteers without diabetes, active liver disease, or significant macular pathology will take either obicetrapib 10 mg or a matching placebo each day for four months. Participants will attend clinic visits every eight weeks for safety checks, blood draws, and eye examinations to measure antioxidant levels in plasma, HDL particles, and retinal tissue. The study compares antioxidant measurements between the obicetrapib and placebo groups to see if the drug changes absorption or distribution of antioxidants. The trial is sponsored by NewAmsterdam Pharma and conducted at a single site in Miami Gardens, Florida.
Who should consider this trial
Good fit: Ideal candidates are healthy adults with visual acuity better than 20/60 in both eyes who do not have type 2 diabetes, active liver disease, or clinically significant macular pathology and who can attend visits in Miami Gardens, Florida.
Not a fit: People with type 2 diabetes, active liver disease, or clinically significant macular pathology are excluded and would not be expected to benefit from participation.
Why it matters
Potential benefit: If successful, obicetrapib could raise antioxidant levels in blood and eye tissues, which might help protect against oxidative damage.
How similar studies have performed: While obicetrapib and related CETP inhibitors have been studied for effects on lipids, using obicetrapib to change antioxidant absorption in plasma, HDL, or eye tissue is largely untested in humans.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Visual acuity \> 20/60 in both eyes with or without corrective lenses Exclusion Criteria: * Type 2 diabetes * Active liver disease * Any clinically significant macular pathology
Where this trial is running
Miami Gardens, Florida
- Excellence Medical Research — Miami Gardens, Florida, United States (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Antioxidant Absorption, Healthy Volunteer